We concluded that TIMP1 might negatively regulates adaptive immune response based on somatic recombination of immune receptors built from a leucine-rich superfamily (P < 0.001 FDR = 0.021) and response to interferon (P < 0.001 FDR = 0.027) may promote the survival of cancer cells (Figs. 5K and 5L). The gene discussed is TIMP1; the disease is cancer.